Common Mistakes in Patent Applications and Their Maintenance

Avoid mistakes in Patent Applications to avoid to delays, rejections, or loss of rights.

Filing and maintaining a patent is a critical process that can significantly impact an inventor’s ability to protect and monetize their intellectual property. However, even seasoned professionals can make errors that lead to delays, rejections, or loss of rights. Below, we outline some common mistakes in patent applications and maintenance and offer tips to avoid them.

1. Insufficient Disclosure

One of the most common … Read More

Patent Strategy

Patent Strategy - Approach to protect Intellectual Property through Patent Process

A patent strategy is a plan or approach that a business or individual develops to protect their intellectual property through the patent process. It involves decisions and actions to maximize the value of patents while minimizing costs and risks.

A well-defined patent strategy can help you safeguard your innovations, gain a competitive edge, and achieve your business objectives.

Key elements of a patent strategy:

Innovation Read More

Understanding Patent in simple terms

Understanding Patent in simple terms

Understanding patents can be a complex topic, this article will break down patent definition and meaning into more manageable concepts for you.

What is Patent?

A patent provides a legal protection by the government to applicant/inventors for their new and useful inventions. In simple terms, applicant/inventor obtains exclusive rights to make, use, and sell their invention for a certain period, usually 20 years from the … Read More

CONTROVERSIAL PATENTS IN INDIA

CONTROVERSIAL PATENTS IN INDIA

Controversial patents in India includes patents surrounded by controversies due to various reasons like disputes over patent validity, infringement, ethical concerns, public health implications, and more.

SOME OF THE MOST CONTROVERSIAL PATENTS IN INDIA

Novarti‘s Gleevec Patent: Cancer drug controversial patent

In 2013, the Indian Supreme Court rejected Novartis’ patent application for the cancer drug Gleevec (Imatinib Mesylate). The decision was significant as it … Read More